ATE424194T1 - Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson - Google Patents

Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson

Info

Publication number
ATE424194T1
ATE424194T1 AT02759761T AT02759761T ATE424194T1 AT E424194 T1 ATE424194 T1 AT E424194T1 AT 02759761 T AT02759761 T AT 02759761T AT 02759761 T AT02759761 T AT 02759761T AT E424194 T1 ATE424194 T1 AT E424194T1
Authority
AT
Austria
Prior art keywords
adenosine
parkinson
disease
treatment
compounds
Prior art date
Application number
AT02759761T
Other languages
English (en)
Inventor
Dan Peters
Lars Christian Roenn
Karin Sandager Nielsen
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Application granted granted Critical
Publication of ATE424194T1 publication Critical patent/ATE424194T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
AT02759761T 2001-04-09 2002-04-04 Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson ATE424194T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200100583 2001-04-09

Publications (1)

Publication Number Publication Date
ATE424194T1 true ATE424194T1 (de) 2009-03-15

Family

ID=8160425

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02759761T ATE424194T1 (de) 2001-04-09 2002-04-04 Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson

Country Status (8)

Country Link
US (1) US7160899B2 (de)
EP (1) EP1379269B1 (de)
JP (1) JP2004529916A (de)
AT (1) ATE424194T1 (de)
CA (1) CA2440196A1 (de)
DE (1) DE60231386D1 (de)
MX (1) MXPA03009185A (de)
WO (1) WO2002080957A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071102A2 (en) * 1999-05-19 2000-11-30 Neurosearch A/S Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
US20040063742A1 (en) * 2001-02-15 2004-04-01 Dan Peters Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity
ES2716404T3 (es) * 2002-01-28 2019-06-12 Kyowa Hakko Kogyo Kk Antagonistas de receptores A2A para su uso en el tratamiento de trastornos del movimiento
MXPA05006790A (es) 2002-12-19 2005-09-08 Schering Corp Usos de antagonistas del receptor adenosina a2a.
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
CN102160865A (zh) 2006-05-16 2011-08-24 诺普神经科学股份有限公司 R(+)和s(-)普拉克索的组合物以及使用该组合物的方法
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US8519148B2 (en) 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
WO2008144931A1 (en) * 2007-05-30 2008-12-04 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
JP2012500283A (ja) * 2008-08-19 2012-01-05 ノップ ニューロサイエンシーズ、インク． （ｒ）−プラミペキソールを使用した組成物並びにその方法
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
AU2010262970A1 (en) * 2009-06-19 2012-01-12 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
RS67279B1 (sr) 2013-07-12 2025-10-31 Areteia Therapeutics Inc Lečenje povišenih nivoa eozinofila i/ili bazofila
EP3033081B1 (de) 2013-08-13 2021-05-12 Knopp Biosciences LLC Zusammensetzungen und verfahren zur behandlung von chronischer nesselsucht
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
WO2018170359A1 (en) * 2017-03-17 2018-09-20 University Of Virginia Patent Foundation Compositions and methods for treating peripheral nerve disease, disorders, and injuries
EP4083044A4 (de) * 2019-12-26 2024-03-27 Zhejiang Vimgreen Pharmaceuticals, Ltd Verwendung von triazolotriazin-derivaten zur behandlung von krankheiten

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4325254A1 (de) 1992-08-10 1994-02-17 Boehringer Ingelheim Kg Unsymmetrisch substituierte Xanthine
US5574060A (en) 1993-08-12 1996-11-12 The United States Of America As Represented By The Department Of Health And Human Services Selective inhibitors of biogenic amine transporters
FR2734264B1 (fr) 1995-05-19 1997-08-01 Lafon Labor Utilisation de derives d'alpha-aminomethyl-3,4-dichlorobenzyl-thioacetamide pour la fabrication d'un medicament inhibant la recapture de la dopamine et nouveaux composes pour cette utilisation
HUP9802433A3 (en) 1995-10-13 2000-03-28 Neurosearch As 8-azabicyclo[3.2.1]oct-2-ene derivatives, their preparation and use
TR199800780T2 (xx) 1995-11-02 1998-07-21 Neurosearch A/S Kayna�m�� tropan t�revleri, haz�rlan��lar� ve kullan�mlar�.
DE69736776T2 (de) * 1996-04-19 2007-01-18 Neurosearch A/S 1-(4-piperidyl)-benzimidazole mit neurotropher aktivität
AU4078397A (en) 1996-08-16 1998-03-06 Allelix Pharm-Eco, L.L.P. Slow-onset, long-lasting dopamine reuptake blockers
US5821386A (en) 1997-08-15 1998-10-13 Allelix-Pharm-Eco L.P. Compounds for treating cocaine abuse
US6001330A (en) 1997-09-12 1999-12-14 Elmaleh; David R. Diagnostic and therapeutic alkylenediamine compounds and process
AU2639299A (en) 1998-02-24 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Remedies/preventives for parkinson's disease
EP1079816A2 (de) 1998-04-23 2001-03-07 Takeda Chemical Industries, Ltd. Pharmazeutische zusammensetzung mit neurotrophischer wirkung
YU63802A (sh) 2000-02-25 2005-06-10 F. Hoffmann-La Roche Ag. Modulatori adenozinskih receptora
WO2001082946A2 (en) 2000-04-28 2001-11-08 Curis, Inc. Neuroprotective compositions

Also Published As

Publication number Publication date
CA2440196A1 (en) 2002-10-17
JP2004529916A (ja) 2004-09-30
MXPA03009185A (es) 2004-02-17
US7160899B2 (en) 2007-01-09
EP1379269B1 (de) 2009-03-04
US20040097540A1 (en) 2004-05-20
EP1379269A1 (de) 2004-01-14
WO2002080957A1 (en) 2002-10-17
DE60231386D1 (de) 2009-04-16

Similar Documents

Publication Publication Date Title
DE60231386D1 (de) Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson
DE602004011401D1 (de) Benzazepinderivate als histamin-h3-antagonisten
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
PT1349839E (pt) Derivados de feniletenilo ou feniletinilo como antagonistas do receptor de glutamato
NZ522326A (en) Adenosine A2A receptor antagonists
DZ2618A1 (fr) Emploi des antagonistes des récepteurs de 5-HT3 dans le traitement de la colopathie.
TR200200408T2 (tr) Yeni spiro bileşikleri
PT1054887E (pt) Derivados biciclicos de piridina e pirimidina como antagonistas de receptores no neuropeptido y
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
DK1129091T3 (da) Antagonister for CRF-receptorer og fremgangsmåder med relation dertil
PA8521501A1 (es) Ligandos para receptores de melanocortina
DE602004018637D1 (de) A2a-adenosinrezeptorantagonisten
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
DK1129096T3 (da) CRF-receptorantagonister og fremgangsmåder, der er relateret dertil
EA200400399A1 (ru) Способы лечения легочных заболеваний
IS6380A (is) Mótlyf viðtaka adenósíns og aðferðir til að búa þau til og nota
PT1200400E (pt) Derivados de pirrolidino-2,3,4-trion-3-oxina substituidas com eficacia como antagonistas do receptor nmda
ATE325117T1 (de) 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
DE60215637D1 (de) Tri- und tetraaza-acenaphthylen-derivate als crf-rezeptor-antagonisten
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
DE502004007387D1 (de) Triazolverbindungen und ihre therapeutische verwendung
BR0000486A (pt) Antagonistas do neuropeptìdeo y

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties